Brief: Apellis To Receive Up To $300 Million From Royalty Purchase Agreement With SOBI
01/07/2025 12:04
July 1 (Reuters) - Apellis Pharmaceuticals Inc APLS.O: APELLIS TO RECEIVE UP TO $300 MILLION FROM ROYALTY PURCHASE AGREEMENT WITH SOBI FOR EX-U.S. ROYALTIES OF ASPAVELI® (SYSTEMIC PEGCETACOPLAN) APELLIS PHARMACEUTICALS INC - RETAINS FULL U.S. COMMERCIALIZATION RIGHTS FOR SYSTEMIC PGCETACOPLAN APELLIS PHARMACEUTICALS INC - EMA CHMP OPINION ON ASPAVELI EXPECTED BEFORE YEAR-END APELLIS PHARMACEUTICALS INC - PDUFA ACTION DATE FOR ASPAVELI IN U.S. IS JULY 28, 2025 Source text: ID:nGNX2fd7gV Further company coverage: APLS.O (((( Reuters.briefs@thomsonreuters.com ;));))